Barclays’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-30,260
| Closed | -$48K | – | 4409 |
|
|
2024
Q1 | $48K | Sell |
30,260
-60,932
| -67% | -$96.7K | ﹤0.01% | 3825 |
|
|
2023
Q4 | $78K | Buy |
91,192
+52,331
| +135% | +$44.8K | ﹤0.01% | 3770 |
|
|
2023
Q3 | $41K | Sell |
38,861
-1,529
| -4% | -$1.61K | ﹤0.01% | 3678 |
|
|
2023
Q2 | $104K | Sell |
40,390
-3,687
| -8% | -$9.49K | ﹤0.01% | 3379 |
|
|
2023
Q1 | $179K | Sell |
44,077
-25,827
| -37% | -$105K | ﹤0.01% | 3216 |
|
|
2022
Q4 | $350K | Buy |
69,904
+26,009
| +59% | +$130K | ﹤0.01% | 2800 |
|
|
2022
Q3 | $575K | Buy |
43,895
+18,459
| +73% | +$242K | ﹤0.01% | 2504 |
|
|
2022
Q2 | $326K | Buy |
25,436
+6,065
| +31% | +$77.7K | ﹤0.01% | 2851 |
|
|
2022
Q1 | $295K | Sell |
19,371
-36,389
| -65% | -$554K | ﹤0.01% | 3102 |
|
|
2021
Q4 | $987K | Buy |
55,760
+23,499
| +73% | +$416K | ﹤0.01% | 2214 |
|
|
2021
Q3 | $679K | Buy |
32,261
+26,059
| +420% | +$548K | ﹤0.01% | 2459 |
|
|
2021
Q2 | $123K | Sell |
6,202
-20,367
| -77% | -$404K | ﹤0.01% | 3072 |
|
|
2021
Q1 | $773K | Buy |
26,569
+10,331
| +64% | +$301K | ﹤0.01% | 2431 |
|
|
2020
Q4 | $492K | Sell |
16,238
-9,158
| -36% | -$277K | ﹤0.01% | 2325 |
|
|
2020
Q3 | $404K | Buy |
25,396
+2,566
| +11% | +$40.8K | ﹤0.01% | 2411 |
|
|
2020
Q2 | $450K | Buy |
22,830
+449
| +2% | +$8.85K | ﹤0.01% | 2377 |
|
|
2020
Q1 | $276K | Sell |
22,381
-20,933
| -48% | -$258K | ﹤0.01% | 2403 |
|
|
2019
Q4 | $800K | Buy |
43,314
+14,398
| +50% | +$266K | ﹤0.01% | 2429 |
|
|
2019
Q3 | $401K | Sell |
28,916
-377
| -1% | -$5.23K | ﹤0.01% | 2722 |
|
|
2019
Q2 | $428K | Buy |
+29,293
| New | +$428K | ﹤0.01% | 2803 |
|